Immunome Inc
IMNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$2B
Close$
$7.27
65.2% downside
Current Fair Value
65.2% downsideOvervalued by 65.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.00 Billion |
|---|---|
| Enterprise Value | $1.78 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.43 |
| Beta | 2.13 |
| Outstanding Shares | 113,272,931 |
Return
| Return on Equity | -48.43% |
|---|---|
| Return on Assets | -44.98% |
| Return on Invested Capital | -48.23% |
Valuation & Multiples
| P/E Ratio | -8.23 |
|---|---|
| PEG | -12.01 |
| Price to Sales | - |
| Price to Book Ratio | 5.23 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -6.99 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$222,222
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.65
Average shareholder expectationRevenue Estimate
$166,667
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2916▼ 481.17% |
|---|---|
| Total Calls | 311,400▲ 15.72% |
| Total Puts | 90,800▼ 93.39% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 104.99%▲ 1.86% |
|---|---|
| Total Invested | $2.52B▼ 0.96% |
| Investors Holding | 211▲ 3.00% |
ESG Score
No data
About Immunome Inc
2,020 employeesImmunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are treated. The company's initi...